A Review of the Clinical Experience with the Angiotensin II Receptor Antagonist Irbesartan

Waeber, Bernard

doi:10.1111/j.1527-3466.2000.tb00038.x

Cited by 8 publications

(2 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the hypotensive effect was observed both in normotensive and hypertensive rats, although it was more accentuated in the latter. Furthermore, the oral administration of 20 mg/kg of irbesartan, an AII receptor antagonist (Brunner, 1997;Waeber, 2000) was used as a control pharmacological antihypertensive drug, produced a reduction of arterial blood pressure. This angiotensin (AT) II antagonist is considered as one of the widely used antihypertensive drugs in the treatment of hypertension with less adverse events compared to other antihypertensive medication (Moller-Nordhorn and Willich, 2003;Malmqvist et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

Fraxinus excelsior L. evokes a hypotensive action in normal and spontaneously hypertensive rats

Eddouks¹,

Maghrani²,

Zeggwagh³

et al. 2005

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Fraxinus excelsior L. evokes a hypotensive action in normal and spontaneously hypertensive rats

Eddouks¹,

Maghrani²,

Zeggwagh³

et al. 2005

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…However, they do not block angiotensin II production completely, because angiotensin II can be generated by non-ACE pathways. Angiotensin II receptor antagonists/blockers represent a relative newer class of antihypertensive agents, developed to overcome some of the deficiencies of ACE inhibitors 4–6. Angiotensin II receptor blockers selectively block AT 1 receptors, preventing binding of angiotensin II, inhibiting the renin angiotensin system, and lowering BP.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan

Gialama¹,

Maniadakis²

2013

VHRM

View full text Add to dashboard Cite

BackgroundHypertension represents a major health problem, affecting more than one billion adults worldwide. Irbesartan, an angiotensin II receptor blocker, is considered to be a highly effective treatment in the management of hypertension. The purpose of this review is to evaluate the efficacy, safety and tolerability profile , and cost-effectiveness of treatment with irbesartan in hypertension.MethodsA review of the literature was conducted using the electronic PubMed and Cochrane Library databases and the Health Economic Evaluations Database of search terms relating to irbesartan efficacy, tolerability, and cost-effectiveness, and the results were utilized.ResultsFindings from the present analysis show that irbesartan either as monotherapy or in combination with other antihypertensive agents can achieve significant reductions in blood pressure, both systolic and diastolic, compared with alternative treatment options. Irbesartan was also found to have a renoprotective effect independent of its blood pressure-lowering in patients with type 2 diabetes and nephropathy. Furthermore, irbesartan demonstrated an excellent safety and tolerability profile , with either lower or equal adverse events compared with placebo and other alternative treatments. In terms of economic analyses, compared with other antihypertensive therapy alternatives, irbesartan was found to be a preferred option, that is less costly and more effective.ConclusionThe evidence indicates that treating patients with hypertension alone or with type 2 diabetes and nephropathy using irbesartan can control hypertension, prolong life, and reduce costs in relation to existing alternatives.

show abstract

Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data

Kumar¹,

Srinivas²

2008

Eur. J. Drug Metabol. Pharmacokinet.

View full text Add to dashboard Cite

Allometric principles have been applied to scale and predict human pharmacokinetic parameters of irbesartan, an important AT1 receptor antagonist. The preclinical data gathered from rats, macaques (monkeys) and dogs were used in the allometric analysis. The use of these species was rationalized because preclinical models based on these species have been used in the evaluation pharmacodynamic activity of irbesartan. The human parameter values for clearance (CL/F), volume of distribution (V/F), and elimination rate constant (Kel) were scaled using simple allometry (CL/F, V/F and Kel) or with correction factors (CL/F). The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted = 9 h; observed = 10-20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted = 456 L; observed = 260 L). The present work presents an opportunity for prospective allometric scaling for the compounds belonging to this important therapeutic class.

show abstract

A Review of the Clinical Experience with the Angiotensin II Receptor Antagonist Irbesartan

Cited by 8 publications

References 64 publications

Fraxinus excelsior L. evokes a hypotensive action in normal and spontaneously hypertensive rats

Fraxinus excelsior L. evokes a hypotensive action in normal and spontaneously hypertensive rats

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan

Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data

Contact Info

Product

Resources

About